This is an aggregated industry headline. Read the full story at FierceBiotech →
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
Sanofi has abandoned plans to seek approval for amlitelimab in atopic dermatitis, admitting that a drug once tipped as potential blockbuster "would not represent a meaningful improvement" to existing treatments.
By FierceBiotech
· Jul 24, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
An FDA advisory committee has recommended that four peptide drugs that were previously restricted because of p…
The WeekDrug Channels ↗
Today's guest post comes from Chip Parkinson, CEO at Gifthealth. Chip discusses how Direct-to-Patient (DTP) mo…
The WeekSTAT News ↗
The Trump administration released its blueprint for U.S. science, calling for shifting hundreds of billions of…